Identification of gefitinib off-targets using a structure-based systems biology approach; their validation with reverse docking and retrospective data mining

Gefitinib, an EGFR tyrosine kinase inhibitor, is used as FDA approved drug in breast cancer and non-small cell lung cancer treatment. However, this drug has certain side effects and complications for which the underlying molecular mechanisms are not well understood. By systems biology based in silic...

Descripción completa

Detalles Bibliográficos
Autores principales: Verma, Nidhi, Rai, Amit Kumar, Kaushik, Vibha, Brünnert, Daniela, Chahar, Kirti Raj, Pandey, Janmejay, Goyal, Pankaj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5032012/
https://www.ncbi.nlm.nih.gov/pubmed/27653775
http://dx.doi.org/10.1038/srep33949

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5032012/
https://www.ncbi.nlm.nih.gov/pubmed/27653775
http://dx.doi.org/10.1038/srep33949

Ejemplares similares